Q-omics provides the consensus-scored TRAJ42 profile across patient tissues and cancer cell-line models. TRAJ42 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TRAJ42 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, TRAJ42 RNA expression shows 11,536 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, KIRC, and LSCC as cancer lineages where TRAJ42 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ42 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ42 survival associations across molecular data types. TRAJ42 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ42 RNA expression–survival associations across cancer types. High TRAJ42 expression shows unfavorable associations in MESO, UCEC and COAD, but favorable associations in LUAD, ESCA and THYM. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify LUAD as the clearest survival context for TRAJ42 RNA expression.
This table summarizes TRAJ42 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ42. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ42 shows lower tumor expression in LUSC and higher tumor expression in KIRC, STAD, HNSC and LUAD. The KIRC box plot shows higher TRAJ42 RNA expression in tumor versus normal tissue (log2 FC = +0.202, t-test p = .001).
This table shows molecular features associated with TRAJ42 in patient tissues and cancer cell lines. In patient samples, TRAJ42 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
